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In October 2020, anti-severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) immunoglobulin G seroprevalence 
among truck drivers and their assistants (TDA) in Kenya 
was 42.3%, higher than among healthcare workers and blood 
donors. Truck drivers and their assistants transport essential 
supplies during the coronavirus disease 2019 pandemic, placing 
them at increased risk of being infected and of transmitting 
SARS-CoV-2 over a wide geographical area.
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Serosurveillance for antibodies to the severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) can be used to 
estimate the cumulative incidence of SARS-CoV-2 infection. 
This is of particular interest among frontline workers, such as 
truck drivers, who are exempted from coronavirus disease 2019 
(COVID-19) restrictions such as curfews and lockdowns.
Shortly after the first locally detected SARS-CoV-2 infection 
in March 2020, the Government of Kenya instituted contain-
ment measures, including travel restrictions. Freight transporta-
tion was excluded from travel restrictions because truckers and 
drivers’ assistants (TDA) were deemed essential workers [1]. In 
May 2020, the Kenya Ministry of Health implemented manda-
tory bimonthly SARS-CoV-2 nucleic acid testing (NAT) for long-
distance TDA, in line with East African Community guidelines 
[2, 3]. Although NAT data can be used to estimate the cumulative 
incidence of SARS-CoV-2 infection [4], accurate estimates are 
dependent on the availability of reliable model parameter values.
There are currently no estimates of SARS-CoV-2 antibody se-
roprevalence among TDA globally. Due to the nature of their 
work, TDA interact with a wide variety of social and profes-
sional contacts over a large geographical area, putting them 
at increased risk of SARS-CoV-2 infection. We undertook a 
serosurvey to estimate the prevalence of SARS-CoV-2 anti-
bodies among TDA in Kenya.
METHODS
Study Design and Participants
A cross-sectional serosurvey was conducted at 3 sites: 1 in 
Kilifi County in South-Eastern Kenya and 2 in Busia County 
in Western Kenya (Supplementary Figure 1). In Kilifi County, 
TDA transporting salt domestically and to East African coun-
tries (eg, Uganda, Rwanda and Burundi) were engaged at salt 
harvesting companies located in Gongoni area, Magarini Sub-
County. In Busia County, TDA were engaged at One Stop Border 
Posts (OSBPs) in 2 border towns, Busia and Malaba. Truckers 
and drivers’ assistants at Busia OSBP and Malaba OSBP typi-
cally transport freight between Mombasa, Kenya and countries 
in East Africa (Supplementary Figure 2).
Truckers and drivers’ assistants were eligible if they were aged 
≥18 years without a medical contraindication for blood sample 
collection. Participation was voluntary and verbal consent was 
sought before blood sample collection. Serosurveillance was con-
ducted as a public health activity requested by the Kenya Ministry 
of Health, and ethical approval for publication of these data was 
obtained from the Kenya Medical Research Institute Scientific and 
Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085).
Patient Consent Statement
The study did not include factors necessitating patient consent.
Data and Sample Collection
Sociodemographic and clinical data, including age, sex, nation-
ality, residence, temperature, and symptoms of illness within 
the previous 2 weeks, were collected by county public health 
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staff (CPHS) and recorded on governmental COVID-19 sur-
veillance forms (Supplementary Forms 1 and 2). Venous blood 
samples were collected using standard blood sample collection 
procedures and labeled with the same unique identifier as na-
sopharyngeal/oropharyngeal (NP/OP) samples. The NP/OP 
NAT results, linked using the unique identifiers, were obtained 
from testing laboratories. Data with personal identifiers were 
retained only by CPHS.
Laboratory Testing
Plasma was extracted from blood samples using standard tech-
niques and stored at −80°C before antibody testing. Thawed 
plasma samples were tested for anti-SARS-CoV-2 immuno-
globulin G (IgG) using a locally validated whole spike enzyme-
linked immunosorbent assay (ELISA) with 93% sensitivity and 
99% specificity, as described previously [5, 6]. Spike ELISA pos-
itivity was defined as a ratio of sample optical density (OD) over 
negative control OD >2. The NP/OP NAT results are routinely 
provided to TDA by CPHS. Serology results were also provided 
to TDA by CPHS.
Statistical Analysis
At least 700 samples were required to estimate seroprevalence 
as low as 2% within a 1% margin of error. Age was categorized 
into 10-year strata. Crude seroprevalence was estimated as the 
number of anti-SARS-CoV-2 IgG-positive samples (OD ratio 
>2) divided by all samples, and associated exact binomial 95% 
confidence intervals (CIs) were calculated. Bayesian adjust-
ment for assay sensitivity and specificity was performed as pre-
viously described [6]. Associations between seropositivity and 
sociodemographic/clinical characteristics were tested using χ 2 
or Fisher’s exact tests. Test-performance-adjusted seropreva-
lence and credible intervals were calculated in R (version 3.6.1) 
with RStan. All other analyses were performed using Stata (ver-
sion 15.1).
RESULTS
The serosurvey was conducted in Magarini between September 
30 and October 23, 2020 and in Busia County on October 
13–15, 2020. In total, 830 TDA (Busia OSBP n = 365; Magarini 
n = 101; Malaba OSBP n = 364) provided a blood sample, rep-
resenting 52.4% of TDA approached (Supplementary Figure 
3). Of the 830 samples, 91.1% were collected between October 
13 and 15, 2020 (Supplementary Figure 4). The median age of 
sampled TDA was 40 years (interquartile range, 34–48 years) 
and 668 (80.5%) were Kenyan. Only 3 (0.4%) of the TDA were 
female (Table 1). Among Kenyan TDA, reported county of 
residence included 31 of the country’s 47 counties. The most 
common counties of residence were Mombasa, Uasin Gishu, 
and Nakuru (Supplementary Table 1). Driver versus assistant 
role was not recorded, but, on the basis of truck driver licensure 
age requirements, at least 53 (6.6%) were assistants (Table 1).
Of 785 TDA with available NAT results, 58 (7.4%) were pos-
itive for SARS-CoV-2 (Table 1); positivity was significantly 
Table 1. Crude and Test-Performance Adjusted Anti-SARS-CoV-2 IgG Seroprevalence Among TDA in Kenya, September 30 to October 23, 2020
Characteristic N Seropositive








Total 830 329 39.6 36.3–43.1 42.3 38.4–46.3
Agea       
<30 years 92 42 45.7 35.2–56.4 49.1 38.1–59.9
30–39 years 276 110 39.9 34.0–45.9 42.4 35.5–49.1
40–49 years 286 116 40.6 34.8–46.5 43.4 37.4–49.9
50–59 years 135 48 35.6 27.5–44.2 38.1 29.2–47.4
>60 years 38 13 34.2 19.6–51.4 37.0 22.3–54.1
Sex       
Male 827 326 39.4 36.1–42.8 42.1 38.1–46.7
Female 3 3 100.0 29.2–100.0 79.6 37.9–99.3
NAT Resulta       
Positive 58 32 55.2 41.5–68.3 59.0 46.0–72.1
Negative 727 270 37.1 33.6–40.8 39.6 35.0–43.9
Nationality       
Kenya 668 262 39.2 35.5–43.0 41.9 37.7–46.0
Other 162 67 41.4 33.7–49.4 44.2 36.3–52.5
Site       
Busia OSBP 365 163 44.7 39.5–49.9 47.9 42.3–53.8
Magarini 101 43 42.6 32.8–52.8 45.2 35.1–55.9
Malaba OSBP 364 123 33.8 28.9–38.9 36.0 30.8–41.9
Abbreviations: IgG, immunoglobulin G; NAT, nucleic acid test; OSBP, One Stop Border Post; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TDA, truck drivers and assistants.
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higher in Magarini (25 of 93; 26.9%) compared to Busia OSBP 
(15 of 348; 4.3%) and Malaba OSBP (18 of 344; 5.2%; P < .001) 
(Supplementary Table 2). None of the 830 TDA reported cur-
rent or previous symptoms of illness. Only 1 individual had a 
temperature of 37.5°C or higher (Supplementary Table 2) and 
the NAT result was negative in that 1 case.
Crude overall anti-SARS-CoV-2 IgG seroprevalence among 
sampled TDA was 39.6% (95% CI, 36.3−43.1). After adjustment 
for assay sensitivity and specificity it was 42.3% (95% cred-
ible interval [CrI], 38.4−46.3). Seroprevalence was highest in 
TDA <30 years of age and lowest among those aged ≥50 years. 
All 3 female TDA were seropositive for anti-SARS-CoV-2 
IgG. Seroprevalence was 39.6% (95% CrI, 35.0−43.9) among 
TDA negative for SARS-CoV-2 by NAT and 59.0% (95% CrI, 
46.0−72.1) among those with a positive SARS-CoV-2 NAT re-
sult. Seroprevalence among Kenyan TDA was comparable to 
that of other nationalities. By site, seroprevalence was highest 
at Busia OSBP and lowest at Malaba OSBP. Crude heterogeneity 
tests and uncertainty intervals for antibody test-adjusted esti-
mates suggested no significant association between seropreva-
lence and age and significant differences in seroprevalence by 
site (Table 1 and Supplementary Table 3).
DISCUSSION
We estimate that approximately 4 in 10 TDA in Kenya had 
been infected with SARS-CoV-2 by late October 2020, as the 
country experienced the initial stages of a second pandemic 
wave (Supplementary Figure 5). This study is notable for being 
the first to report SARS-CoV-2 seroprevalence among TDA.
Anti-SARS-CoV-2 IgG seroprevalence among TDA was 
more than 4-fold higher compared to average seroprevalence 
among Kenyan blood donors by September 2020 [7] and 2-fold 
higher compared to average seroprevalence in healthcare 
workers (HCWs) across 5 Kenyan health facilities by October 
2020 [8]. As such, the findings suggest that the cumulative inci-
dence of SARS-CoV-2 among TDA in Kenya was higher than in 
the general population and in other frontline workers.
Outside Kenya, some studies found 44%−45% seropreva-
lence of SARS-CoV-2 antibodies among HCWs, comparable 
to that among TDA in Kenya [9–11]. However, meta-analyses 
of studies globally estimated SARS-CoV-2 antibody prevalence 
among HCWs at 7% by July 2020 [12] and 9% by August 2020 
[13]. Taken together, these data suggest that exposure to SARS-
CoV-2 among TDA was higher than among HCWs in most 
settings.
To date, few studies have assessed SARS-CoV-2 antibody 
prevalence in nonhealthcare frontline workers. Seroprevalence 
was 38% seroprevalence among male migrant supermarket 
workers in Kuwait in May to June 2020 [14]. Elsewhere, how-
ever, seroprevalence among non-HCWs has been lower, ran-
ging from 1% [15] to 22% [16].
None of the NAT-positive TDA reported symptoms within 
2 weeks of testing, suggesting predominantly asymptomatic 
COVID-19 among TDA. Although data on symptoms may have 
been subject to reporting bias, 93% of SARS-CoV-2 infections 
confirmed in Kenya by October 23, 2020 were asymptomatic 
[17]. The similarity in anti-SARS-CoV-2 antibody seroposi-
tivity among Kenyan and non-Kenyan TDA indicates predom-
inantly occupation-related exposure to SARS-CoV-2. The fact 
that seroprevalence differed by sampling site suggests some het-
erogeneity in exposure risk.
Despite sampling at 3 different sites, we cannot be sure that 
the sample included are representative of all TDA in Kenya, or 
even those transiting through these sites. Participation in the 
serosurvey was voluntary, only half of those approached agreed 
to be sampled, and sociodemographic data for the target pop-
ulation are not available. However, data on county of residence 
for Kenyan TDA indicates representation from most counties. 
Seroprevalence estimates did not account for clustering by site 
or by driver-assistant pairs. The use of antibodies to estimate cu-
mulative incidence of SARS-CoV-2 infection assumes universal 
seroconversion, minimal mortality, and antibody persistence. If 
these assumptions are incorrect—for example, there is evidence 
suggestive of antibody waning [18–20]—the cumulative inci-
dence of infection would be underestimated. To minimize bias 
due to assay sensitivity and specificity, adjusted seroprevalence 
estimates were calculated.
CONCLUSIONS
These findings indicate substantial cumulative incidence of 
SARS-CoV-2 infection—most of which was asymptomatic—
among TDA in Kenya, despite prevention measures. The oc-
cupational nature of haulage entails interaction with many 
contacts over large geographical areas; as such, TDA may un-
intentionally contribute to the spread of emerging infections. 
These findings illustrate the challenge of infection prevention 
within an occupational group whose role in sustaining supply 
chains remains vital during a pandemic. In addition, they un-
derscore the importance of national and regional preparedness 
plans for the safe continuation of haulage in future pandemics.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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